163 related articles for article (PubMed ID: 28833582)
1. A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs.
Sato M; Veir JK; Legare M; Lappin MR
J Vet Intern Med; 2017 Sep; 31(5):1502-1507. PubMed ID: 28833582
[TBL] [Abstract][Full Text] [Related]
2. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy.
Gregory CR; Stewart A; Sturges B; DeManvelle T; Cannon A; Ortega T; Harb M; Morris RE
Transplant Proc; 1998 Dec; 30(8):4143-8. PubMed ID: 9865328
[No Abstract] [Full Text] [Related]
3. Efficacy of leflunomide for treatment of refractory inflammatory colorectal polyps in 15 Miniature Dachshunds.
Fukushima K; Eguchi N; Ohno K; Kanemoto H; Takahashi M; Igarashi H; Ohmi A; Nakashima K; Tsujimoto H
J Vet Med Sci; 2016 Feb; 78(2):265-9. PubMed ID: 26460312
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).
Colopy SA; Baker TA; Muir P
J Am Vet Med Assoc; 2010 Feb; 236(3):312-8. PubMed ID: 20113244
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory drugs and their application to the management of canine immune-mediated disease.
Whitley NT; Day MJ
J Small Anim Pract; 2011 Feb; 52(2):70-85. PubMed ID: 21265846
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of cyclosporine and leflunomide in treating inflammatory colorectal polyps in miniature dachshunds.
Tani A; Seno T; Yokoyama N; Nakagawa T; Tomiyasu H; Goto-Koshino Y; Tsujimoto H; Ohno K
J Vet Med Sci; 2020 Apr; 82(4):437-440. PubMed ID: 32062634
[TBL] [Abstract][Full Text] [Related]
7. Treatment of presumptive primary immune-mediated thrombocytopenia with mycophenolate mofetil versus cyclosporine in dogs.
Cummings FO; Rizzo SA
J Small Anim Pract; 2017 Feb; 58(2):96-102. PubMed ID: 28160307
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of leflunomide in the canine renal transplantation model.
McChesney LP; Xiao F; Sankary HN; Foster PF; Sharma S; Haklin M; Williams JW
Transplantation; 1994 Jun; 57(12):1717-22. PubMed ID: 8016874
[TBL] [Abstract][Full Text] [Related]
9. [Immunosuppressive therapy in dogs and cats. Properties of drugs and their use in various immune-mediated diseases].
Rieder J; Mischke R
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Apr; 46(2):105-118. PubMed ID: 29727898
[TBL] [Abstract][Full Text] [Related]
10. Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011).
Wang A; Smith JR; Creevy KE
J Small Anim Pract; 2013 Aug; 54(8):399-404. PubMed ID: 23879827
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide: new indication. In psoriatic rheumatism: too many risks, too little efficacy.
Prescrire Int; 2005 Aug; 14(78):123-6. PubMed ID: 16106593
[TBL] [Abstract][Full Text] [Related]
12. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.
Maddison P; Kiely P; Kirkham B; Lawson T; Moots R; Proudfoot D; Reece R; Scott D; Sword R; Taggart A; Thwaites C; Williams E
Rheumatology (Oxford); 2005 Mar; 44(3):280-6. PubMed ID: 15657072
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of adverse effects of mycophenolate mofetil administration to dogs with immune-mediated disease.
Fukushima K; Lappin M; Legare M; Veir J
J Vet Intern Med; 2021 Sep; 35(5):2215-2221. PubMed ID: 34231261
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
Kaltwasser JP; Nash P; Gladman D; Rosen CF; Behrens F; Jones P; Wollenhaupt J; Falk FG; Mease P;
Arthritis Rheum; 2004 Jun; 50(6):1939-50. PubMed ID: 15188371
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity.
de Souza RC; de Souza FHC; Miossi R; Shinjo SK
Clin Exp Rheumatol; 2017; 35(6):1011-1013. PubMed ID: 28422003
[TBL] [Abstract][Full Text] [Related]
16. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
[TBL] [Abstract][Full Text] [Related]
17. [Leflunomide--a new drug for pharmacological immunomodulation].
Wozel G; Pfeiffer C
Hautarzt; 2002 May; 53(5):309-15. PubMed ID: 12063741
[TBL] [Abstract][Full Text] [Related]
18. Leflunomide use in renal transplantation.
Leca N
Curr Opin Organ Transplant; 2009 Aug; 14(4):370-4. PubMed ID: 19512928
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Evans' syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog.
Bianco D; Hardy RM
J Am Anim Hosp Assoc; 2009; 45(3):147-50. PubMed ID: 19411652
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
Poór G; Strand V;
Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
